Compare GSK plc (GSK) vs JD.Com Inc (JD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs JD.Com Inc — how do they compare? GSK plc trades at $46.61 (market cap $91.88B), while JD.Com Inc trades at $27.14 (market cap $36.62B). The key difference: GSK plc is far larger — about 2.5× JD.Com Inc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and JD.Com Inc for 85 Days on average.
| GSK | JD | |
|---|---|---|
Market Cap | $91.88B | $36.62B |
Volume | 7,730,529 | 6,571,477 |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $34.53 |
52-Week Low | $43.24 | $25.19 |
Typical Hold Time | 93 Days | 85 Days |
Enterprise Value | $111.88B | $19.26B |
Dividend Yield | 3.9% | 3.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
JD.com trades at $27.17, up 0.5% on the day, with strong analyst support (69.6% buy ratings) and a consensus price target of $35.86 suggesting 32% upside. Recent quarterly earnings have consistently beaten expectations, though revenue growth has slowed to 0.3% year-over-year for 2026. The stock appears fundamentally undervalued with a P/E of 17.9 and P/S of 0.2, while technical indicators show a mixed but slightly bullish bias with key support at $27.
JD offers significant valuation upside potential given its low multiples and strong cash position, but faces headwinds from slowing revenue growth and regulatory scrutiny of its European expansion. The company's robust balance sheet with $234 billion cash provides stability, though competitive pressures in Chinese e-commerce and macroeconomic concerns remain key risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
